Middle East Pharmaceutical Industries Co (SAU:4016) Beneish M-Score: -2.06 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SAU:4016 Middle East Pharmaceutical Industries Co SAU:4016
22 GF Score
Price ﷼60.55
! 3 Warning Signs
View Full Analysis

What is Middle East Pharmaceutical Industries Co Beneish M-Score?

Middle East Pharmaceutical Industries Co SAU:4016 +0.92% 22 Beneish M-Score is -2.06 as of Jul. 21, 2026. GuruFocus rates SAU:4016 with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 910 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks worse than 76.26% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Middle East Pharmaceutical Industries Co's Beneish M-Score or its related term are showing as below:

SAU:4016' s Beneish M-Score Range Over the Past 10 Years
Min: -2.25   Med: -2.15   Max: -1.48
Current: -2.06

During the past 3 years, the highest Beneish M-Score of Middle East Pharmaceutical Industries Co was -1.48. The lowest was -2.25. And the median was -2.15.


Middle East Pharmaceutical Industries Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Middle East Pharmaceutical Industries Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Middle East Pharmaceutical Industries Co Beneish M-Score Chart

Middle East Pharmaceutical Industries Co Annual Data
Trend Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 -2.25

Middle East Pharmaceutical Industries Co Quarterly Data
Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.48 -2.23 -2.25 -2.06

SAU:4016 vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Middle East Pharmaceutical Industries Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Middle East Pharmaceutical Industries Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Middle East Pharmaceutical Industries Co's Beneish M-Score falls into.


SAU:4016
22GF Score
Middle East Pharmaceutical Industries Co SAU:4016
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Middle East Pharmaceutical Industries Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Middle East Pharmaceutical Industries Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0846+0.528 * 0.9982+0.404 * 1.0732+0.892 * 1.187+0.115 * 0.9148
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0202+4.679 * 0.044482-0.327 * 1.1493
=-2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ﷼287.0 Mil.
Revenue was 130.127 + 137.518 + 107.95 + 117.656 = ﷼493.3 Mil.
Gross Profit was 80.617 + 90.465 + 62.474 + 73.632 = ﷼307.2 Mil.
Total Current Assets was ﷼428.9 Mil.
Total Assets was ﷼626.5 Mil.
Property, Plant and Equipment(Net PPE) was ﷼133.9 Mil.
Depreciation, Depletion and Amortization(DDA) was ﷼20.7 Mil.
Selling, General, & Admin. Expense(SGA) was ﷼89.3 Mil.
Total Current Liabilities was ﷼150.3 Mil.
Long-Term Debt & Capital Lease Obligation was ﷼28.0 Mil.
Net Income was 26.899 + 44.522 + 8.278 + 24.811 = ﷼104.5 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ﷼0.0 Mil.
Cash Flow from Operations was 11.332 + 10.5 + 24.796 + 30.015 = ﷼76.6 Mil.
Total Receivables was ﷼222.9 Mil.
Revenue was 97.361 + 135.988 + 81.061 + 101.132 = ﷼415.5 Mil.
Gross Profit was 60.267 + 89.082 + 45.701 + 63.283 = ﷼258.3 Mil.
Total Current Assets was ﷼373.7 Mil.
Total Assets was ﷼548.3 Mil.
Property, Plant and Equipment(Net PPE) was ﷼122.6 Mil.
Depreciation, Depletion and Amortization(DDA) was ﷼17.1 Mil.
Selling, General, & Admin. Expense(SGA) was ﷼73.8 Mil.
Total Current Liabilities was ﷼135.8 Mil.
Long-Term Debt & Capital Lease Obligation was ﷼0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(286.963 / 493.251) / (222.893 / 415.542)
=0.581779 / 0.536391
=1.0846

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(258.333 / 415.542) / (307.188 / 493.251)
=0.621677 / 0.622782
=0.9982

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (428.858 + 133.873) / 626.478) / (1 - (373.724 + 122.622) / 548.335)
=0.101755 / 0.094812
=1.0732

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=493.251 / 415.542
=1.187

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(17.082 / (17.082 + 122.622)) / (20.653 / (20.653 + 133.873))
=0.122273 / 0.133654
=0.9148

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(89.347 / 493.251) / (73.782 / 415.542)
=0.181139 / 0.177556
=1.0202

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((27.965 + 150.285) / 626.478) / ((0 + 135.752) / 548.335)
=0.284527 / 0.247571
=1.1493

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(104.51 - 0 - 76.643) / 626.478
=0.044482

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Middle East Pharmaceutical Industries Co has a M-score of -2.06 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.06 mean?
Middle East Pharmaceutical Industries Co (SAU:4016) has a Beneish M-Score of -2.06 as of Jul. 21, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Middle East Pharmaceutical Industries Co and its competitors. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #694 out of 910 companies in the Drug Manufacturers industry, placing it in the top 76.3%.
Is Middle East Pharmaceutical Industries Co's Beneish M-Score too high?
Middle East Pharmaceutical Industries Co's current Beneish M-Score is -2.06. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #694 out of 910 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #694 out of 910 companies for Beneish M-Score. This places Middle East Pharmaceutical Industries Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Middle East Pharmaceutical Industries Co and its competitors. Middle East Pharmaceutical Industries Co's current Beneish M-Score is -2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current Beneish M-Score of -2.06. The current Beneish M-Score is -2.06. Middle East Pharmaceutical Industries Co's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current Beneish M-Score is -2.06 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Middle East Pharmaceutical Industries Co Business Description

Address 8146 King Muhammad V, Sulaimaniyah, P.O. Box 4180, Riyadh, SAU, 11491
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
22GF Score

Get the complete analysis for SAU:4016

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

﷼60.55
Price